Clinical Trial Update: Phase 1-2 Trial HCQ Plus TACE in Unresectable HCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1-2 trial evaluating hydroxychloroquine plus transarterial chemoembolization (TACE) in unresectable hepatocellular carcinoma was terminated with posted re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Hydroxychloroquine (hydroxychloroquine)
• Transarterial chemoembolization (chemotherapy with embolization (various agents))

Snippet

Sponsor: Abramson Cancer Center at Penn Medicine | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-04-20